Evolent Health to Participate in Upcoming Investor Conferences
WASHINGTON, Aug. 22, 2019 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH) ("Evolent"), a company providing an integrated value-based care platform to the nation's leading provider and payer organizations, today announced that Chief Executive Officer and Co-Founder Frank Williams, President and Co-Founder Seth Blackley, Chief Financial Officer John Johnson and Executive Vice President, Corporate Performance Nicky McGrane will participate in upcoming investor conferences.
Mr. Williams, Mr. Johnson and Mr. McGrane will present at the Wells Fargo Securities 2019 Healthcare Conference in Boston on Wednesday, September 4, 2019 at 10:50 a.m. EST. A live audio-only webcast and related presentation materials will be available on the investor relations section of Evolent's website at http://ir.evolenthealth.com/.
Mr. Williams, Mr. Johnson and Mr. McGrane will present at the Robert W. Baird 2019 Global Healthcare Conference in New York on Thursday, September 5, 2019 at 9:05 a.m. EST.
Mr. Blackley, Mr. Johnson and Mr. McGrane will present at the Morgan Stanley 2019 Global Healthcare Conference in New York on Tuesday, September 10, 2019 at 10:35 a.m. EST.
About Evolent Health Evolent Health partners with leading provider and payer organizations to achieve superior clinical and financial results in value-based care and under full-risk arrangements. With a provider heritage and over 20 years of health plan administration experience, Evolent partners with more than 35 health care organizations to actively manage care across Medicare, Medicaid, commercial and self-funded adult and pediatric populations. With the experience to drive change, Evolent confidently stands by a commitment to achieve results. For more information, visit evolenthealth.com.
Contacts: Bob East or Asher Dewhurst 443.213.0500 Investor Relations [email protected]
Three major challenges poised to confront the nation's clinical laboratories, genetic test companies, and anatomic pathology laboratories will be major topics when a top-flight roster of lab experts, innovators, and lab leaders gather in New Orleans...
Surmodics, Inc. , a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that second quarter of fiscal year 2024 financial results will be released before the market opens on Wednesday,...
Merck , known as MSD outside the United States and Canada, announced that Health Canada has granted approval of KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, in combination with fluoropyrimidine- and platinum-containing-chemotherapy, for the...
Globe Life Inc. will release First Quarter 2024 earnings after the market closes on Monday, April 22, 2024. At that time, a copy of the Company's First Quarter 2024 earnings press release and any other financial and statistical information about...
GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, announced US Food and Drug Administration (FDA) has granted the clinical trial approval for GFH925 (KRAS G12C inhibitor) in a...
César A. Lara, MD, introduces a groundbreaking solution for pain relief in the Tampa Bay area. Red Laser Therapy leverages the power of medical-grade red laser light to effectively address various types of pain, providing patients with a noninvasive...